Duyuru • Aug 14
Eikon Therapeutics, Inc. Announces Appointment of Ma. Fatima D. Francisco as Independent Director and to the Compensation Committee Eikon Therapeutics, Inc. appointed Ma. Fatima D. Francisco as an independent director to its Board of Directors, where Ms. Francisco will also serve on the Board’s Compensation Committee. Ms. Francisco most recently served as Chief Executive Officer, Baby, Feminine and Family Care at The Procter & Gamble Company, where she led one of the company's largest global business units. During her more than 35-year career at Procter & Gamble, she has held numerous leadership positions across marketing, innovation, commercial operations, and general management. She also serves on the Board of Directors of HP Inc. and Nestlé S.A., and previously served on the Board of Directors of Organon & Co. Duyuru • Aug 13
Eikon Therapeutics Selects Dose For TeLuRide-006 Adaptive Phase 2/3 Trial Of EIK1001 In Advanced Melanoma Eikon Therapeutics, Inc. announced the selection of a dose of 0.60 mg/m2 that will be employed in future for all patients randomized to receive EIK1001 in the TeLuRide-006 trial. This decision aligns with a recommendation from an independent DMC following a prespecified analysis of unblinded data. The DMC recommended that the TeLuRide-006 study continue as planned in all other respects. EIK1001 is an investigational, systemically administered dual-agonist of Toll-like receptors 7 and 8 designed to stimulate both innate and adaptive immune responses to malignancy. In Phase 1 trials of EIK1001, single-agent activity was observed in patients with advanced solid tumors. This mechanism may complement the antitumor immune response engendered by PD-(L)1 blockade. TeLuRide-006 (NCT06697301) is a global, multicenter, randomized, double-blind, adaptive Phase 2/3 registrational trial of EIK1001 or placebo, in combination with pembrolizumab, as first-line therapy for participants with advanced cutaneous melanoma. Duyuru • Aug 11
Eikon Therapeutics, Inc. Announces Appointment of Johnny Bennett, Ph.D. to Scientific Advisory Board Eikon Therapeutics, Inc. had announced the addition of Johnny Bennett, Ph.D. to its Scientific Advisory Board. Dr. Bennett currently served as Vice President and Head of Discovery Chemistry at Merck Research Laboratories. A native of Scotland, Dr. Johnny Bennett earned his undergraduate and Ph.D. degrees from Heriot-Watt University in Edinburgh before beginning his career with N.V. Organon in the Netherlands in 1997. There, he worked across neuroscience and cardiovascular disease, with his neuroscience research culminating in the discovery of sugammadex (Bridion), the first medicine developed to rapidly reverse neuromuscular blockade following surgery. In recognition of this achievement, he was a co-recipient of both the American Chemical Society Heroes of Chemistry Award and the Royal Society of Chemistry Malcolm Campbell Memorial Award for outstanding contributions to the biological and medical sciences. After relocating to the United States in 2011, Dr. Bennett joined Merck as Senior Director of Discovery Chemistry in West Point before moving to lead the Discovery Chemistry organization at the company’s Boston site in 2012. He had since taken on a series of increasingly broad leadership roles within Merck’s Discovery Chemistry group, and was promoted to Vice President in 2022. Dr. Bennett also served as interim Head of Discovery Oncology in 2024. Earlier in 2026, Dr. Bennett was promoted to his current role of Vice President and Head of Discovery Chemistry. Dr. Bennett joined a distinguished group of scientists serving on the company’s Scientific Advisory Board, including: Eric Betzig, Ph.D., is a co-founder of Eikon, a professor at the University of California, Berkeley, and a 2014 Nobel laureate whose pioneering work in super-resolution microscopy helped provide the technological foundation for Eikon’s proprietary single molecule tracking (SMT) platform. Thomas Cech, Ph.D., is a Distinguished Professor of Biochemistry at the University of Colorado, Boulder and a 1989 Nobel laureate whose research established the ability of certain RNA molecules to behave as enzymes. Trey Ideker, Ph.D., is the Director of the Big Data Institute at the University of Oxford (UK), and a Professor of Medicine at the University of California, San Diego. He is a leader in computational approaches to understanding complex biological processes, including those associated with disease pathogenesis. Robert “Tij” Tjian, Ph.D., is a co-founder of Eikon, a professor of biochemistry, biophysics and structural biology and the Li Ka Shing Chancellor's Chair in Biology at the University of California, Berkeley, and former president of the Howard Hughes Medical Institute. Wendy B. Young, Ph.D., is an accomplished medicinal chemist and drug discovery executive who previously led small-molecule drug discovery research at Genentech and now advises biotechnology companies and serves as an advisor to GV (Google Ventures). Duyuru • Jul 27
Eikon Therapeutics Doses First Patient in TeLuRide-008 Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer Eikon Therapeutics, Inc. has dosed the first patient in TeLuRide-008, a Phase 2/3 registrational study evaluating EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy as first-line therapy for treatment-naïve patients with stage 4 Non-Small Cell Lung Cancer (NSCLC). TeLuRide-008 (NCT07365319) is a global, multicenter, double-blind, placebo-controlled, randomized adaptive Phase 2/3 study to evaluate the clinical activity and safety of EIK1001 administered intravenously in combination with pembrolizumab and histology-appropriate chemotherapy to systemic therapy-naïve participants with Stage 4 non-squamous or squamous NSCLC. The specific chemotherapy for non-squamous histology is pemetrexed plus either carboplatin or cisplatin, while for squamous histology it is carboplatin plus paclitaxel or nab-paclitaxel. The study is being conducted in two phases (Phase 2 and Phase 3) and will be analyzed in three parts (dose optimization, dose expansion and confirmatory hypothesis testing). TeLuRide-008 is the second registrational phase 2/3 trial for EIK1001. TeLuRide-006 (NCT06697301), which is enrolling patients with advanced malignant melanoma, was initiated in May of 2025. EIK1001 is an investigational, systemically administered dual-agonist of Toll-like receptors 7 and 8 designed to stimulate both innate and adaptive immune responses. In Phase 1 trials of EIK1001, single-agent activity was observed in patients with advanced malignancy. This mechanism may complement the antitumor immune response engendered by PD-(L)1 blockade. EIK1001 has been studied in over 500 patients and observed to be well-tolerated to date, both as a monotherapy, and in combination with PD-(L)1-specific antibody-based therapy. Board Change • Jul 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Fama Francisco was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Duyuru • Jun 09
Eikon Therapeutics, Inc. Announces Appointment of Ma. Fatima D. Francisco as Independent Director and Compensation Committee Member, Effective June 15, 2026 Eikon Therapeutics, Inc. announced the appointment of Ma. Fatima D. Francisco as an independent director to Eikon’s Board of Directors, effective June 15, 2026. Ms. Francisco will also serve on the Compensation Committee of the Board. Ms. Francisco most recently served as Chief Executive Officer, Baby, Feminine and Family Care at The Procter & Gamble Company, where she led one of the company's largest global business units. During her more than 35-year career at Procter & Gamble, she has held numerous leadership positions across marketing, innovation, commercial operations and general management. She also serves on the Board of Directors of HP Inc. and Nestle S.A., and previously served on the Board of Directors of Organon & Co. Ms. Francisco holds a Bachelor of Science degree in Business Administration and Marketing from the University of the Philippines. New Risk • Mar 31
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$235m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$235m free cash flow). Earnings are forecast to decline by an average of 6.8% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$456m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Recent Insider Transactions • Feb 09
Independent Director recently bought US$2.0m worth of stock On the 4th of February, Kenneth Frazier bought around 111k shares on-market at roughly US$18.00 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Duyuru • Feb 05
Eikon Therapeutics, Inc. has completed an IPO in the amount of $381.1968 million. Eikon Therapeutics, Inc. has completed an IPO in the amount of $381.1968 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 21,177,600
Price\Range: $18
Discount Per Security: $1.26
Transaction Features: Sponsor Backed Offering